Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016 (2016), Article ID 9132052, 5 pages
Research Article

The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes

1Diabetes Unit, Niguarda Cà Granda Hospital, 20162 Milan, Italy
2Diabetes Unit, Cantù Hospital, 20081 Abbiategrasso, Italy

Received 24 May 2016; Revised 14 August 2016; Accepted 20 September 2016

Academic Editor: Vittorio Unfer

Copyright © 2016 Basilio Pintaudi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Inositol has been used as a supplement in treating several pathologies such as PCOS, metabolic syndrome, and gestational diabetes. Both myo-inositol and its isomer d-chiro-inositol showed insulin mimetic effects in conditions of insulin resistance. Type 2 diabetes (T2DM) is a condition typically caused by insulin resistance. There is a lack of evidence of inositol use in T2DM. We evaluated the effectiveness and safety of myo-inositol and d-chiro-inositol treatment in T2DM. This was a pilot study involving a consecutive sample of patients with T2DM with suboptimal glycemic control (HbA1c 7.0–10.0%) already treated with glucose-lowering agents. Patients (23.1% males, mean age of years) took for three months a combination of myo-inositol (550 mg) and d-chiro-inositol (13.8 mg) orally twice a day as add-on supplement to their glucose-lowering drugs. Possible occurrence of side effects was investigated. After three months of treatment fasting blood glucose ( versus ; ) and HbA1c levels ( versus ; ) significantly decreased compared to baseline. There was no significant difference in blood pressure, lipid profile, and BMI levels. None of the participants reported side effects. In conclusion, a supplementation with a combination of myo- and d-chiro-inositol is an effective and safe strategy for improving glycemic control in T2DM.